Flush with $165M IPO cash, Zentalis entices Tybourne, OrbiMed to fund a $20M China joint venture

Weeks after jumping into the public eye with an upsized $165 million IPO ($190 million if you count the overallotment), setting an upbeat tone for the later pandemic biotech floats, Zentalis Pharmaceuticals is following up with a plan to take three of its experimental cancer drugs to China.